Skip to main content
INOVIO PHARMACEUTICALS, INC. logo

INOVIO PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · INO ISIN · US45773H4092 LEI · 529900B9W875XDZXTM97 US Manufacturing
Open in API
Filings indexed 1,003 across all filing types
Latest filing 2025-11-14 Major Shareholding Noti…
Country US United States of America
Listing US INO

About INOVIO PHARMACEUTICALS, INC.

https://www.inovio.com/

INOVIO PHARMACEUTICALS, INC. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines. The company's core technology centers on designing proprietary DNA plasmids—small, circular DNA molecules that instruct the body's cells to produce specific, targeted proteins to combat disease. These DNA medicines are delivered into cells using the company's proprietary investigational CELLECTRA® smart devices. This platform is designed to enable in vivo protein production and achieve therapeutic effect without the use of chemical adjuvants, lipid nanoparticles, or viral vectors. The company's development pipeline targets HPV-related diseases, various cancers, and infectious diseases.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-13 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 11, 2025, by Inovio Pharmaceuticals, Inc. It reports the entry into a material definitive agreement related to a public offering of common stock, including details about the underwriting agreement, shares issued, pricing, and expected proceeds. The document includes exhibits such as the underwriting agreement and legal opinions. There are no financial statements or detailed financial performance data included, only an announcement of a financing transaction. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is 7552 characters, sufficient to contain substantive information about the financing event rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2025-11-12 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a Preliminary Prospectus Supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to a public offering of common stock by Inovio Pharmaceuticals, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company overview. The document is a registration and offering prospectus supplement, which is a capital raising document rather than a financial report or earnings release. It does not contain financial statements or management discussion of financial results but focuses on the terms and details of the stock offering. Therefore, it fits the category of Capital/Financing Update (CAP).
2025-11-12 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.